Source:http://linkedlifedata.com/resource/pubmed/id/14508660
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
10
|
pubmed:dateCreated |
2003-10-21
|
pubmed:abstractText |
The risk factors for development of paradoxical response were studied in a cohort of 104 patients with culture-documented Mycobacterium tuberculosis infection. Paradoxical deterioration occurred in 16 (15.4%) patients (case group) during antituberculosis therapy, involving lungs and pleura (n=4), spine and paraspinal tissue (n=5), intracranium (n=3), peritoneum (n=2), bone and joint (n=1), and lymph node (n=1). The median time from commencement of treatment to paradoxical deterioration was 56 days (range, 20-109 days). Compared with 53 patients without clinical deterioration after antituberculosis therapy (control group), patients with paradoxical response were more likely to have extrapulmonary involvement (62.5% vs. 17.0%; P<0.05) at initial diagnosis, to have lower baseline lymphocyte counts (672+/-315 cells/microl vs. 1,328+/-467 cells/microl; P<0.001), and to exhibit a greater surge in lymphocyte counts (627+/-465 cells/microl vs. 225+/-216 cells/microl; P<0.05) during paradoxical response. Further studies on lymphocyte subsets and cytokine levels would be useful in understanding the exact immunological mechanisms involved in immunorestitution.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0934-9723
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
22
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
597-602
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:14508660-Adult,
pubmed-meshheading:14508660-Age Distribution,
pubmed-meshheading:14508660-Aged,
pubmed-meshheading:14508660-Antitubercular Agents,
pubmed-meshheading:14508660-Case-Control Studies,
pubmed-meshheading:14508660-Chi-Square Distribution,
pubmed-meshheading:14508660-Cohort Studies,
pubmed-meshheading:14508660-Disease Progression,
pubmed-meshheading:14508660-Female,
pubmed-meshheading:14508660-Follow-Up Studies,
pubmed-meshheading:14508660-HIV Seronegativity,
pubmed-meshheading:14508660-Humans,
pubmed-meshheading:14508660-Incidence,
pubmed-meshheading:14508660-Male,
pubmed-meshheading:14508660-Middle Aged,
pubmed-meshheading:14508660-Mycobacterium tuberculosis,
pubmed-meshheading:14508660-Probability,
pubmed-meshheading:14508660-Risk Assessment,
pubmed-meshheading:14508660-Severity of Illness Index,
pubmed-meshheading:14508660-Sex Distribution,
pubmed-meshheading:14508660-Treatment Outcome,
pubmed-meshheading:14508660-Tuberculin Test,
pubmed-meshheading:14508660-Tuberculosis, Pulmonary
|
pubmed:year |
2003
|
pubmed:articleTitle |
Risk factors for development of paradoxical response during antituberculosis therapy in HIV-negative patients.
|
pubmed:affiliation |
Division of Infectious Diseases, Center of Infection, University Pathology Building, The University of Hong Kong, Queen Mary Hospital, Hong Kong.
|
pubmed:publicationType |
Journal Article,
Comparative Study
|